C1GALT1C1 and colorectal cancer: Additionally, the targeted suppression of the C1galt1c1 gene using CRISPR/Cas9 technology results in increased levels of Tn antigen on the surface of the colorectal cancer cell line MC38 (MC38-Tnhigh) (63).